SkyePharma

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, SkyePharma sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials none currently recruiting 7 completed later-stage tilt upper quartile by trial count

SkyePharma: 7 sponsored US clinical trials, none currently recruiting.

SkyePharma sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 5 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Asthma, with 2 trials.

Upper-quartile sponsor footprint

SkyePharma sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

7 total, page 1 of 1

COMPLETED Phase 3

A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005

NCT00747318
COMPLETED Phase 2

Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma

NCT00734292
COMPLETED Phase 1

A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands

NCT00657774
COMPLETED Phase 3

A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults

NCT00649025
COMPLETED Phase 3

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma

NCT00393991
COMPLETED Phase 3

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma

NCT00393952
COMPLETED Phase 3

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma

NCT00394199

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1
Phase 3 5

Therapeutic Areas

Asthma 2

How the SkyePharma archive is shaped

7 indexed studies, none listed as recruiting (0% open); 7 completed (100%).

Phase mix: 5 late (III/IV) vs 2 early (I/II) (later-stage heavy).

Top condition: Asthma (2 trials), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

SkyePharma: archived-pipeline peers nationwide

Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

SkyePharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share SkyePharma3M4Life Research89bioAbbott Diagnostics Division10xBio22nd Century Group23andMe3-C Institute for Social Development
SkyePharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

SkyePharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this SkyePharma page

7 registered trials is a research-attention snapshot, not an endorsement of SkyePharma or any single study.

  • None of SkyePharma's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Asthma is the condition SkyePharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Asthma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. SkyePharma pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.